NCT01521702View on ClinicalTrials.gov

NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Pancreas Cancer
Interventions
DRUG

Neoadjuvant chemotherapy

four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,

PROCEDURE

surgery and Adjuvant chemotherapy

surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.

Trial Locations (1)

13009

Institut Paoli Calmettes, Marseille

All Listed Sponsors
lead

Institut Paoli-Calmettes

OTHER

NCT01521702 - NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer | Biotech Hunter | Biotech Hunter